Redx Pharma PLC has seen its valuation more than double after selling off another preclinical asset with Jazz Pharmaceuticals PLC getting its hands on the UK firm's pan-RAF inhibitor program.
As part of the agreement, Redx will receive an upfront fee of $3.5m in cash but is eligible to receive up to $203m in development, regulatory and commercial milestone payments,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?